购物车 
-
Curcumin
NMR and HPLC COA下载 MSDS下载 - Names：
Curcumin (Diferuloylmethane), Lipooxygenase inhibitor
- CAS号：
458-37-7
MDL Number： MFCD00008365 - MF(分子式)： C21H20O6 MW(分子量)： 368.38
- EINECS:207-280-5 Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
Curcumin (Diferuloylmethane), Lipooxygenase inhibitor姜黄素是姜黄和咖喱中的主要黄色素，具有抗氧化、抗炎和抗肿瘤活性。 它抑制一氧化氮 (NO) 的产生 (IC50 = 6 μM) 并降低 LPS 刺激的 RAW 264.7 细胞中的诱导型一氧化氮合酶 (iNOS) 活性。 姜黄素抑制 HMC-1 肥大细胞释放组胺和炎性细胞因子 TNF-α、IL-1β、IL-6 和 IL-8。
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| FF0909-20mg | 20mg | 分析对照品 | ¥ 168.00 | ¥ 168.00 | Instock1days | ¥ 0.00 | ||
| SY0003-25g | 25g | 98% | ¥ 182.00 | ¥ 182.00 | Instock1days | ¥ 0.00 | ||
| SY0003-5g | 5g | 98% | ¥ 58.00 | ¥ 58.00 | Instock1days | ¥ 0.00 |
| 中文别名 | 458-37-7; 姜黄色素; 姜黄素;川芎内酯 B;克扣明;脂氧合酶抑制剂; |
| 英文别名 | Curcumin;Diferuloylmethane;Natural yellow 3;Turmeric yellow,;Curcuma;Indian saffron;Turmeric;Lipooxygenase inhibitor; |
| CAS号 | 458-37-7 |
| Inchi | InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3-,8-4- |
| InchiKey | VFLDPWHFBUODDF-VHOZIDCHSA-N |
| 分子式 Molecular Weight | C21H20O6 |
| 分子量 Formula | 368.38 |
| 溶解度Solubility | 0.1 M NaOH: >3 mg/ml 10 mM Na2CO3: <50 ug/ml Acetone: >20 mg/ml Acetone:10 mM Na2CO3 (50:50): >5 mg/ml Water: <100 ug/ml |
| 性状 | Solid |
| 储藏条件 Storage conditions | 储存温度 -20°C |
姜黄素(Curcumin,458-37-7)毒理性质：
姜黄素(CAS:458-37-7;英文名:Curcumin;)实验注意事项：
1.使用458-37-7实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.使用458-37-7实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品458-37-7的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。
5.取药品458-37-7时尽量采用多个药勺分别使用，使用后清洗干净。
6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。
大规格定制：定制产品请将信息发送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:姜黄素蒸汽压,姜黄素合成,姜黄素标准,姜黄素应用,姜黄素合成,姜黄素沸点,姜黄素闪点,姜黄素用途,姜黄素溶解度,姜黄素价格,姜黄素作用,姜黄素结构式,姜黄素用处
| 动物 | 测试类型 | 途径 | 实验摄入量 (标准摄入量) | 影响 | 文献来源 |
| mouse | LD50 | intraperitoneal | 1500mg/kg (1500mg/kg) | Indian Journal of Medical Research. Vol. 64, Pg. 601, 1976. | |
| mouse | LD50 | oral | > 2gm/kg (2000mg/kg) | Journal of Pharmacy and Pharmacology. Vol. 25, Pg. 447, 1973. | |
| rat | LD | oral | > 2gm/kg (2000mg/kg) | Planta Medica. Vol. 64, Pg. 353, 1998. |
姜黄素(CAS:458-37-7;英文名:Curcumin;)实验注意事项：
1.使用458-37-7实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.使用458-37-7实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品458-37-7的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。
5.取药品458-37-7时尽量采用多个药勺分别使用，使用后清洗干净。
6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。
大规格定制：定制产品请将信息发送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:姜黄素蒸汽压,姜黄素合成,姜黄素标准,姜黄素应用,姜黄素合成,姜黄素沸点,姜黄素闪点,姜黄素用途,姜黄素溶解度,姜黄素价格,姜黄素作用,姜黄素结构式,姜黄素用处
| 产品说明 | 姜黄素(458-37-7)易溶于冰乙酸,姜黄素能溶于醇,姜黄素不溶于醚带淡绿色荧先,姜黄素溶于碱呈红棕色,姜黄素加酸于碱液后变为淡黄色. |
| Introduction | Curcumin(458-37-7) is a phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties. |
| Application1 | Curcumin is a yellow-orange dye, NOS2 regulator, and inhibitor of NF-κB, 5-LO, Cox-2, COP9, and p300/CBP. |
| Application2 | 酸碱指示剂，pH7.8(黄)～9.2(红棕) |
| Application3 | 显色反应测铍、锆和镁，硼酸盐和试剂 |
1.Curcumin is a beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa. It has a role as a metabolite, an anti-inflammatory agent, an antineoplastic agent, a hepatoprotective agent, a flavouring agent, a biological pigment, a nutraceutical, an antifungal agent, a dye, a lipoxygenase inhibitor, a ligand, a radical scavenger, a contraceptive drug, an EC 3.5.1.98 (histone deacetylase) inhibitor, an immunomodulator, an iron chelator, a neuroprotective agent, a food colouring, an EC 1.1.1.21 (aldehyde reductase) inhibitor, an EC 1.1.1.25 (shikimate dehydrogenase) inhibitor, an EC 1.1.1.205 (IMP dehydrogenase) inhibitor, an EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor, an EC 1.8.1.9 (thioredoxin reductase) inhibitor and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It is a polyphenol, a beta-diketone, an enone, a diarylheptanoid and an aromatic ether. It derives from a ferulic acid.
2.Curcumin is a phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties. Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C. These effects may play a role in the agent's observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer.
2.Curcumin is a phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties. Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C. These effects may play a role in the agent's observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer.
| 警示图 | |
| 危险性 | warning |
| 危险性警示 | Not Available |
| 安全声明 | H315,H319,H335 |
| 安全防护 | P261,P305+P351+P338 |
| 备注 | 避免吸入，误食以及与皮肤接触 |
| Gupta SC, Patchva S, Aggarwal BB: Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013 Jan;15(1):195-218. doi: 10.1208/s12248-012-9432-8. Epub 2012 Nov 10. [PMID:23143785] |
| Lopes-Rodrigues V, Sousa E, Vasconcelos MH: Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives. Pharmaceuticals (Basel). 2016 Nov 10;9(4). pii: ph9040071. doi: 10.3390/ph |
| Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer PMID 33292283; Cancer cell international 2020 Nov; 20(1):560 (Review A |
| Quercetin, Epigallocatechin Gallate, Curcumin, and Resveratrol: From Dietary Sources to Human MicroRNA Modulation PMID 31878082; Molecules (Basel, Switzerland) 2019 Dec; 25(1): (Review Article) Name m |
| A systemic review on the antioxidant and anti-inflammatory effects of resveratrol, curcumin, and dietary nitric oxide supplementation on human cardiovascular health PMID 32428778; Nutrition research ( |
1.Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases/PMID 33104076; Journal of visualized experiments : JoVE 2020 Oct; ?(164):/Name matches: GSH; glutathione curcumin
Abstract:Glutathione S-transferases (GSTs) are metabolic enzymes responsible for the elimination of endogenous or exogenous electrophilic compounds by glutathione (GSH) conjugation. In addition, GSTs are regulators of mitogen-activated protein kinases (MAPKs) involved in apoptotic pathways. Overexpression of GSTs is correlated with decreased therapeutic efficacy among patients undergoing chemotherapy with electrophilic alkylating agents. Using GST inhibitors may be a potential solution to reverse this tendency and augment treatment potency. Achieving this goal requires the discovery of such compounds, with an accurate, quick, and easy enzyme assay. A spectrophotometric protocol using 1-chloro-2,4-dinitrobenzene (CDNB) as the substrate is the most employed method in the literature. However, already described GST inhibition experiments do not provide a protocol detailing each stage of an optimal inhibition assay, such as the measurement of the Michaelis-Menten constant (Km) for CDNB or indication of the employed enzyme concentration, crucial parameters to assess the inhibition potency of a tested compound. Hence, with this protocol, we describe each step of an optimized spectrophotometric GST enzyme assay, to screen libraries of potential inhibitors. We explain the calculation of both the half-maximal inhibitory concentration (IC50) and the constant of inhibition (Ki)-two characteristics used to measure the potency of an enzyme inhibitor. The method described can be implemented using a pool of GSTs extracted from cells or pure recombinant human GSTs, namely GST alpha 1 (GSTA1), GST mu 1 (GSTM1) or GST pi 1 (GSTP1). However, this protocol cannot be applied to GST theta 1 (GSTT1), as CDNB is not a substrate for this isoform. This method was used to test the inhibition potency of curcumin using GSTs from equine liver. Curcumin is a molecule exhibiting anti-cancer properties and showed affinity towards GST isoforms after in silico docking predictions. We demonstrated that curcumin is a potent competitive GST inhibitor, with an IC50 of 31.6 ± 3.6 µM and a Ki of 23.2 ± 3.2 µM. Curcumin has potential to be combined with electrophilic chemotherapy medication to improve its efficacy.
2.Obstacles against the Marketing of Curcumin as a Drug/PMID 32927725; International journal of molecular sciences 2020 Sep; 21(18): (Review Article)/Name matches: cancer curcumin
Abstract:Among the extensive public and scientific interest in the use of phytochemicals to prevent or treat human diseases in recent years, natural compounds have been highly investigated to elucidate their therapeutic effect on chronic human diseases including cancer, cardiovascular disease, and neurodegenerative disease. Curcumin, an active principle of the perennial herb Curcuma longa, has attracted an increasing research interest over the last half-century due to its diversity of molecular targets, including transcription factors, enzymes, protein kinases, growth factors, inflammatory cytokines, receptors, and it's interesting pharmacological activities. Despite that, the clinical effectiveness of the native curcumin is weak, owing to its low bioavailability and rapid metabolism. Preclinical data obtained from animal models and phase I clinical studies done in human volunteers confirmed a small amount of intestinal absorption, hepatic first pass effect, and some degree of intestinal metabolism, might explain its poor systemic availability when it is given via the oral route. During the last decade, researchers have attempted with new pharmaceutical methods such as nanoparticles, liposomes, micelles, solid dispersions, emulsions, and microspheres to improve the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with a varying range of enhanced bioavailability. This manuscript critically reviews the available scientific evidence on the basic and clinical effects and molecular targets of curcumin. We also discuss its pharmacokinetic and problems for marketing curcumin as a drug.
3.Key Developments in the Potential of Curcumin for the Treatment of Peripheral Neuropathies/PMID 33023197; Antioxidants (Basel, Switzerland) 2020 Oct; 9(10): (Review Article)/Name matches: cancers curcumin
Abstract:Peripheral neuropathies (PN) can be triggered after metabolic diseases, traumatic peripheral nerve injury, genetic mutations, toxic substances, and/or inflammation. PN is a major clinical problem, affecting many patients and with few effective therapeutics. Recently, interest in natural dietary compounds, such as polyphenols, in human health has led to a great deal of research, especially in PN. Curcumin is a polyphenol extracted from the root of Curcuma longa. This molecule has long been used in Asian medicine for its anti-inflammatory, antibacterial, and antioxidant properties. However, like numerous polyphenols, curcumin has a very low bioavailability and a very fast metabolism. This review addresses multiple aspects of curcumin in PN, including bioavailability issues, new formulations, observations in animal behavioral tests, electrophysiological, histological, and molecular aspects, and clinical trials published to date. The, review covers in vitro and in vivo studies, with a special focus on the molecular mechanisms of curcumin (anti-inflammatory, antioxidant, anti-endoplasmic reticulum stress (anti-ER-stress), neuroprotection, and glial protection). This review provides for the first time an overview of curcumin in the treatment of PN. Finally, because PN are associated with numerous pathologies (e.g., cancers, diabetes, addiction, inflammatory disease...), this review is likely to interest a large audience.
Abstract:Glutathione S-transferases (GSTs) are metabolic enzymes responsible for the elimination of endogenous or exogenous electrophilic compounds by glutathione (GSH) conjugation. In addition, GSTs are regulators of mitogen-activated protein kinases (MAPKs) involved in apoptotic pathways. Overexpression of GSTs is correlated with decreased therapeutic efficacy among patients undergoing chemotherapy with electrophilic alkylating agents. Using GST inhibitors may be a potential solution to reverse this tendency and augment treatment potency. Achieving this goal requires the discovery of such compounds, with an accurate, quick, and easy enzyme assay. A spectrophotometric protocol using 1-chloro-2,4-dinitrobenzene (CDNB) as the substrate is the most employed method in the literature. However, already described GST inhibition experiments do not provide a protocol detailing each stage of an optimal inhibition assay, such as the measurement of the Michaelis-Menten constant (Km) for CDNB or indication of the employed enzyme concentration, crucial parameters to assess the inhibition potency of a tested compound. Hence, with this protocol, we describe each step of an optimized spectrophotometric GST enzyme assay, to screen libraries of potential inhibitors. We explain the calculation of both the half-maximal inhibitory concentration (IC50) and the constant of inhibition (Ki)-two characteristics used to measure the potency of an enzyme inhibitor. The method described can be implemented using a pool of GSTs extracted from cells or pure recombinant human GSTs, namely GST alpha 1 (GSTA1), GST mu 1 (GSTM1) or GST pi 1 (GSTP1). However, this protocol cannot be applied to GST theta 1 (GSTT1), as CDNB is not a substrate for this isoform. This method was used to test the inhibition potency of curcumin using GSTs from equine liver. Curcumin is a molecule exhibiting anti-cancer properties and showed affinity towards GST isoforms after in silico docking predictions. We demonstrated that curcumin is a potent competitive GST inhibitor, with an IC50 of 31.6 ± 3.6 µM and a Ki of 23.2 ± 3.2 µM. Curcumin has potential to be combined with electrophilic chemotherapy medication to improve its efficacy.
2.Obstacles against the Marketing of Curcumin as a Drug/PMID 32927725; International journal of molecular sciences 2020 Sep; 21(18): (Review Article)/Name matches: cancer curcumin
Abstract:Among the extensive public and scientific interest in the use of phytochemicals to prevent or treat human diseases in recent years, natural compounds have been highly investigated to elucidate their therapeutic effect on chronic human diseases including cancer, cardiovascular disease, and neurodegenerative disease. Curcumin, an active principle of the perennial herb Curcuma longa, has attracted an increasing research interest over the last half-century due to its diversity of molecular targets, including transcription factors, enzymes, protein kinases, growth factors, inflammatory cytokines, receptors, and it's interesting pharmacological activities. Despite that, the clinical effectiveness of the native curcumin is weak, owing to its low bioavailability and rapid metabolism. Preclinical data obtained from animal models and phase I clinical studies done in human volunteers confirmed a small amount of intestinal absorption, hepatic first pass effect, and some degree of intestinal metabolism, might explain its poor systemic availability when it is given via the oral route. During the last decade, researchers have attempted with new pharmaceutical methods such as nanoparticles, liposomes, micelles, solid dispersions, emulsions, and microspheres to improve the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with a varying range of enhanced bioavailability. This manuscript critically reviews the available scientific evidence on the basic and clinical effects and molecular targets of curcumin. We also discuss its pharmacokinetic and problems for marketing curcumin as a drug.
3.Key Developments in the Potential of Curcumin for the Treatment of Peripheral Neuropathies/PMID 33023197; Antioxidants (Basel, Switzerland) 2020 Oct; 9(10): (Review Article)/Name matches: cancers curcumin
Abstract:Peripheral neuropathies (PN) can be triggered after metabolic diseases, traumatic peripheral nerve injury, genetic mutations, toxic substances, and/or inflammation. PN is a major clinical problem, affecting many patients and with few effective therapeutics. Recently, interest in natural dietary compounds, such as polyphenols, in human health has led to a great deal of research, especially in PN. Curcumin is a polyphenol extracted from the root of Curcuma longa. This molecule has long been used in Asian medicine for its anti-inflammatory, antibacterial, and antioxidant properties. However, like numerous polyphenols, curcumin has a very low bioavailability and a very fast metabolism. This review addresses multiple aspects of curcumin in PN, including bioavailability issues, new formulations, observations in animal behavioral tests, electrophysiological, histological, and molecular aspects, and clinical trials published to date. The, review covers in vitro and in vivo studies, with a special focus on the molecular mechanisms of curcumin (anti-inflammatory, antioxidant, anti-endoplasmic reticulum stress (anti-ER-stress), neuroprotection, and glial protection). This review provides for the first time an overview of curcumin in the treatment of PN. Finally, because PN are associated with numerous pathologies (e.g., cancers, diabetes, addiction, inflammatory disease...), this review is likely to interest a large audience.
对不起，暂无产品评价！
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
怎么做细胞爬片免疫组化染色实验
细胞爬片免疫组化染色，是通过细胞爬片是让玻片浸在细胞培养基内，细胞在玻片上生长，主要用于组织学，免疫组织化学...
2020/7/20 22:04:33
提取病毒RNA的实验方法
提取病毒RNA方法分别有：异硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
细胞培养耗材技术领先性
细胞培养板行业面临的核心痛点是：常规TC处理后表面亲水角随时间衰减，影响长期培养稳定性，BIOFOUNT高分...
2026/4/28 15:12:51
细胞培养耗材关键性能
细胞培养板的水接触角作为表面润湿性的核心指标，直接影响细胞贴壁、增殖、分化及功能表达，其中40°（低接触角/...
2026/4/28 14:52:44
chelex 100树脂国产替代之路-BIOFOUNT范德生物
Chelex 100螯合离子交换树脂对铜、铁和其他重金属?的偏好显著高于对钠、钾等一价阳离子的偏好。它对二价...
2025/11/4 14:22:46
9月开学季——助研新学期 范德送好礼
2025/8/28 15:30:55
Waxfilm 实验室封口膜：技术与国际市场的双重突破
在实验室耗材领域，封口膜是保障实验准确性与稳定性的关键产品之一。近年来，Waxfilm?实验室封口膜凭借其卓...
2025/5/13 13:03:40
Waxfilm实验室封口膜的5大突破
Waxfilm实验室封口膜作为生物功能膜领域的国产技术突破和品牌突破，是生物领域中国技术发展的缩影。
2025/5/6 17:02:07
各种微流控芯片键合方法的优缺点
微流控芯片键合：目前主要有激光焊接、热压键合、胶键合、超音波焊接，每种方法都有各自的优缺点。本文主要介绍聚酯...
2023/7/28 10:43:09
新一代微流控键合解决方案
微流控键合解决方案：微流控芯片制造的一个重要环节，也是最容易被忽视的--芯片键合。其中一个重要因素是：微流控...
2023/7/27 12:44:28
